When was Adimab founded?

Adimab was founded in 2007 and raised its 1st funding round within a year of its incorporation.

Where is Adimab located?

Adimab is headquartered in Lebanon, United States.

How many employees does Adimab have?

As of Sep 30, 2026, the latest employee count at Adimab is 136.

Is Adimab a funded company?

Adimab is a funded company, having raised a total of $35.4M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 20, 2007.

When was the latest funding round of Adimab?

Adimab's latest funding was a $***** Series F round on Apr 02, 2012, with participation from 0 investor. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $1.39B in funding in 2026 to date.

Where does Adimab rank among its competitors?

Adimab ranks 2nd amongst 898 active competitors, of which 59 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Helogen, which secured $7.1M in Sep, 2026.

Who are the top competitors of Adimab?

Adimab's top competitors include Alloy Therapeutics, Manifold Bio and Simulations Plus. Among them, Helogen secured the most recent funding round in September, 2026.

Adimab - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of yeast based discovery platforms for therapeutic protein engineering. This technology enables the discovery and optimization of fully human antibodies and multispecific formats. The process incorporates synthetic and immune libraries to facilitate antigen acquisition, high-throughput sorting, and hit characterization. Engineered candidates undergo assessment for binding, stability, and expression to ensure clinical developability. Services include platform transfer and support for generating therapeutic leads.

Website: adimab.com
Email ID: *****@adimab.com
Phone Number: +1 **********

Key Metrics

Founded Year

2007

Location

Lebanon, United States

Stage

Series F

Total Funding

$35.4M in 6 rounds

Latest Funding Round

Series F, Apr 02, 2012, $*****

Investors

Polaris Partners & 11 more

Ranked

2^nd among 898 active competitors

Employee Count

136 as on Sep 30, 2026

Investment & Acquisitions

Adagio

Similar Companies

Alloy Therapeutics & 919 more

View Adimab's full profile

Adimab is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Adimab, Llc CIN: 80-0669559 , United States, Active	Dec 14, 2010	-	121 (As on Dec 31, 2021)	-

Adimab has raised a total funding of $35.4M over 6 rounds. Its first funding round was on Jul 20, 2007. Adimab has 12 institutional investors.

Here is the list of recent funding rounds of Adimab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2012	9900487	Series F	7481223	7023109	3763735	4852760
Nov 29, 2010	5681930	Series E	4505809	2258816	6119245	2604283
Oct 06, 2009	9928754	Series D	7199756	4173617	Google Ventures	Orbimed & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Adimab's funding rounds and investors

The founders of Adimab is Tillman Gerngross.

Here are the details of Adimab's key team members:

Tillman Gerngross: Co-Founder of Adimab and founder of 1 other company.
Contact Info: 1 email address

View details of Adimab's Founder profiles and Board Members

Adimab's employee count trend

Adimab has 136 employees as of Sep 26. Here is Adimab's employee count trend over the years:

Uncover Adimab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Adimab include Alloy Therapeutics, Manifold Bio and Simulations Plus. Here is the list of Top 10 competitors of Adimab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alloy Therapeutics 2017, Lexington (United States), Series E	Provider of drug discovery services	$157M	8VC, Mubadala & 11 others	71/100
2nd	Adimab 2007, Lebanon (United States), Series F	Developer of yeast based discovery platforms for therapeutic protein engineering	$35.4M	Mithril, Premji Invest & 10 others	61/100
3rd	Manifold Bio 2018, United States, Series A	Developer of tissue-targeted therapeutics using in vivo screening and AI design	$78.2M	Playground Global, Triatomic & 8 others	60/100
4th	Simulations Plus 1996, Lancaster (United States), Acquired	Developer of modeling and simulation software and consulting services provider	-	FDA, NIH & 1 others	60/100
5th	Biocom California 1995, San Diego (United States), Acquired	CRO focused on drug discovery & development for multiple therapeutic areas	-	-	55/100
6th	ZETA 1989, Lieboch (Austria), Unfunded	Provider of engineering, procurement, construction management, and validation for biopharma	-	-	54/100
7th	ArcaScience 2018, Paris (France), Seed	Developer of AI models for patient-centric insights in drug development	$7M	The Moon Venture, Kima Ventures & 5 others	53/100
8th	Sygnature Discovery 2004, Nottingham (United Kingdom), Series A	Provider of integrated drug discovery and development research services	-	Rothschild & Co, Torreal & 4 others	53/100
9th	Helogen 2024, Mountain View (United States), Seed	Provider of space-based biomanufacturing and drug discovery services	$7.1M	RRE Ventures, Blisce & 3 others	52/100
10th	Superluminal Medicines 2022, Boston (United States), Series B	Generative biological and chemical company focused on drug discovery	$223M	RA Capital Management, BVF Partners & 9 others	51/100